Europe Point of Care Testing Devices Market is Expected to Reach EUR 7.2 Billion by 2022 Owing to Promising Growth in Demand of Infectious, Cardiac and Drug of Abuse POCT Devices: Ken Research
Western European countries especially Germany, Italy and United Kingdom have led the market in Europe in terms of manufacturing & consumption of POCT devices. Application of POCT devices in diverse fields of defence, forensics and oncology has led the market in the region.
Mergers and acquisitions (M&A) has been a crucial competitive strategy for players to capture higher market share, access new technology and to expand product offerings in Europe. Data management of POCT has emerged as an upcoming revenue stream for these companies.
Blood Glucose POCT, Infectious POCT and Cardiac POCT would be the leading product segments in terms of sales by the end of the forecast period.
POCT market in Europe has been estimated to grow registering a CAGR of close to 6% in the forecast period. This growth would be supported by the launch of new products, entry of new players, innovative technological revolution and increase in reliability on POCT products by home patients & institutional buyers. Technology innovation in molecular diagnostics is a major driver within the infectious disease POCT for HAIs and STDs. HIV-1, HCV, c.difficle, Chlamydia, H. Pylori, Strep A/B, Influenza A/B, RSV, Ebola and Zika have widespread in Europe during the review period. Highly sensitive cardiac troponins that are the efficacy equivalent to centralized lab testing will increase the adoption of POC cardiac markers in POC settings. CK-MB, myoglobin, BNP, NT-proBNP and D-dimers are simultaneously being used in emergency settings. Inevitable pharamcoeconomic benefits in POC cardiac testing propels this segment to achieve its highest growth potential. Increase in reliability & trust in POCT devices by home users & hospitals, more incidence of diseases such as HIV, infectious, cardiac and others, increase in the number of hospitals, clinics, pathology labs in Europe, growth in nano technology and chip-on-phone miniaturization would provide major thrust to the market.
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...
Summary
Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...